SCM
CCXI

Stevens Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Stevens Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12,146
Closed -$88K – 1137
2017
Q1 		$88K Buy
+12,146
New +$87.5K ﹤0.01% 820

Other funds holding CCXI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stevens Capital Management's CCXI Position: Q2 2017 in Review

Stevens Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q2 2017, closing a stake of 12,146 shares — an estimated $88K sold.

Stevens Capital Management first reported a position in CCXI in Q1 2017 and held it in 1 quarter. The position peaked at $88K in Q1 2017. 88 funds tracked by Wall St. Rank hold CCXI as of Q2 2017.

  • Stevens Capital Management reported no remaining ChemoCentryx, Inc. position as of Q2 2017 after selling out during the quarter.
  • Stevens Capital Management sold 12,146 ChemoCentryx, Inc. shares in Q2 2017, an estimated $88K.
  • Stevens Capital Management first reported a position in ChemoCentryx, Inc. in Q1 2017 and held it in 1 quarter.
  • Stevens Capital Management's ChemoCentryx, Inc. position peaked at $88K in Q1 2017.
  • 88 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2017.

Based on Stevens Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.